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Abstract  
BACKGROUND: Vitiligo is an acquired pigmentary cutaneous disease, characterised by the progressive loss of 
melanocytes, resulting in hypopigmented skin areas which progressively become amelanotic. Classically, vitiligo 
treatments are unsatisfactory and challenging. Despite the continuous introduction of new therapies, phototherapy 
is still the mainstay for vitiligo repigmentation. 
AIM: The aim of this multicenter observational retrospective study was to evaluate the efficacy and safety of the 
nb - UVB micro - phototherapy (BIOSKIN EVOLUTION®), used alone or in associations with an oral Janus kinase 
inhibitor (Tofacitinib citrate), in the treatment of stable or active forms of localised vitiligo. 
MATERIAL AND METHODS: Fifty eight patients had been treated with n-UVB micro-photootherapy (Group A); 9 
patients had been treated with phototherapy plus Tofacitinb citrate (Group B). 
RESULTS: Among Group A, 42 patients (72%) obtained a re-pigmentation rate higher than 75%, with a medium 
value of 77%. 11 patients (19%) achieved a marked improvement of the clinical findings with a repigmentation 
rate between 50-75%; 4 patients (8%) showed a moderate response with a lesional repigmentation of 25-50%. 
Only one patient (1%) had a poor response to the phototherapeutic treatment 
CONCLUSION: Nb - UVB micro-focused phototherapy is one of the most effective therapeutic options for vitiligo 
treatment. The association of micro-focused phototherapy to Tofacitinib citrate seems to provide better clinical 
results in term of repigmentation rate. 
 
 
 
 
Introduction 
 
Vitiligo is an acquired, chronic, cutaneous 
hypopigmentary disorder, which results in the 
progressive loss of melanocytes from the epidermis 
and its appendages. 
Even if the precise aetiology and pathobiology 
of the disease are still unclear [1], recent data support 
that vitiligo is a T - cell-mediated autoimmune disease, 
maybe triggered by oxidative stress [2]. Many data 
support the autoimmune nature of the disease, such 
as the evidence of autoimmune T cells epidermotropic 
T cells exerting anti melanocytic cytotoxicity activity 
[3], the presence of circulating antibodies versus 
melanocyte antigens [4][5], the association with 
another kind of autoimmune syndromes [6], and the 
clinical response to immunosuppressive therapies [7]. 
Since the deep psychological impact of vitiligo on 
patients and their quality of life [8], to treat the disease 
is very important. 
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The aim of this multicenter observational 
retrospective study was to evaluate the efficacy and 
safety of the nb - UVB micro - phototherapy (BIOSKIN 
EVOLUTION®), used alone or in associations with an 
oral Janus kinase inhibitor (Tofacitinib citrate), in the 
treatment of stable or active forms of localized vitiligo. 
 
 
Patients and Methods 
 
This observational retrospective study has 
been conducted in Italy, Germany, Croatia, Bulgaria, 
America and Australia. 
We evaluated 67 subjects (44 women, 23 
men), aged from 25 to 61 years, who suffered from 
stable or active vitiligo Vulgaris by more than 2 years 
and less than 10. In the recent past (more than 5 
months), none of them had been treated for the 
cutaneous disease. Nine of those patients (7 women, 
2 men) were also affected by rheumatoid arthritis 
since more than 3 years (mean duration: 5 years). 
Those patients were in treatment with Tofacitinib 
citrate (10 mg/die), an oral Janus kinase inhibitor. We 
decided to treat all the patients with BIOSKIN 
EVOLUTION®; a special cold light generator micro-
focused phototherapy. BIOSKIN EVOLUTION® can 
provide a spectrum of intensity up to 400 mW/cm
2
 with 
a peak of emission at 311 nm.  
Patients had been irradiated once every three 
weeks for a total of 12 sessions, with an average dose 
of 50 mW/cm
2
. The starting dose of irradiation was 
20% less than the minimal erythema dose (MED), 
which had been evaluated on a vitiliginous area of 
each patient, during a test, performed 3 days before 
the treatment.  
Time of emission and spot diameters were 
regulated by the operator, on the base of the clinical 
characteristic of the patients. In the following sessions 
of treatment, we progressively increased the 
irradiation dose by 20% until the development of 
erythema was noted. When was noted, the dose of 
the following treatment was diminished by 20% in the 
erythematous area. 
For all patients, digital images of the 
cutaneous lesions, both with normal ambient light and 
with Wood’s lamp, have been obtained before the 
treatment beginning and at each session, for all the 
treatment period. Response to the treatment was 
determined by assigning to each lesion a 0% score 
before therapy and a second percentage value at the 
end of the same, to represent the level of 
repigmentation. 
 
 
Results 
At the end of the treatment, we evaluated the 
repigmentation rate achieved by every single patient 
treated with BIOSKIN EVOLUTION® alone (Group A) 
or in association with oral Tofacitinib citrate (Group B). 
Among Group A, 42 patients (72%) obtained a re-
pigmentation rate higher than 75%, with a medium 
value of 77%. Eleven patients (19%) achieved a 
marked improvement of the clinical findings with a 
repigmentation rate between 50 - 75%; four patients 
(8%) showed a moderate response with a lesional 
repigmentation of 25 - 50%. Only one patient (1%) 
had a poor response to the phototherapeutic 
treatment. In any case, we did not observe side 
effects. 
Surprising, the Group B patients showed 
better results in term of repigmentation rate in 
comparison to the patients of Group A. All the 9 
subjects achieved a nearly complete re-pigmentation 
of the vitiliginous areas, with a re -pigmentation rate of 
92%. Also in Group B, we did not observe side 
effects. 
 
 
Discussion 
 
In this retrospective study, we evaluated the 
treatment of 67 patient affected by a stable or active 
form of localised vitiligo with BIOSKIN EVOLUTION®, 
a micro-focused phototherapy device (peak of 
emission of 311 nm), used alone or in association to 
oral Tofacitinib citrate, an oral Janus kinase inhibitor. 
As we had supposed, the study confirms the 
effectiveness and safe-profile of nb - UVB micro-
focused phototherapy in the treatment of localised 
forms of vitiligo. As well known, nb - UVB micro-
focused phototherapy is now considered as one of the 
best treatment for localised vitiligo. As the classical 
phototherapeutic devices, the micro-focused one act 
stimulating silent melanocytes and modulating the 
immune skin system. Differently by classical devices, 
the micro-focused one has the major advantages that, 
treating only skin lesions, the operator may use more 
appropriate doses achieving better results in less time 
and in a safer way, reducing the side effects due to 
radiations [9][10][11]. Moreover, another important 
data has emerged from our retrospective study: the 
combination of BIOSKIN EVOLUTION® to systemic 
Tofacitinib citrate, allows to achieve better clinical 
results in term of repigmentation rate. 
Tofacitinib citrate is an oral Janus kinase 
inhibitor. Janus kinases (JAKs) are intracellular 
protein kinases, crucial for the transmission of 
extracellular cytokines and cells communication. Even 
if they act in different ways (e.g. cells growth and 
maturation), JAKs have a fundamental role for innate 
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and adaptive immunity. Recent data have shown that 
their up-regulation is implicated in autoimmune 
disorders (e.g. rheumatoid arthritis), which may be 
successfully treated with JAKs inhibitors, such as 
Tofacitinib citrate, for their immunosuppressive and 
anti-inflammatory actions [13][14][15]. 
In our case, patients treated with micro-
focused phototherapy plus Tofacitinib citrate achieved 
better results in term of repigmentation 
(repigmentation rate of 92%) than phototherapy alone. 
This can be explained by the imbalance of 
proinflammatory cytokines, mainly derived from 
The/Thl7 lymphocytes, in vitiligo [16]. 
In conclusion, nb - UVB micro-focused 
phototherapy is one of the most effective therapeutic 
options for vitiligo treatment. The association of micro-
focused phototherapy to Tofacitinib citrate seems to 
provide better clinical results in term of repigmentation 
rate. New studies have now to be conducted to 
elucidate the exact mechanism of actions and the 
possibility to use this therapeutic protocol for the 
treatment of vitiligo. 
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